Literature DB >> 12168115

Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter.

Jing Liu1, Wei-Guo Zou, Ming-Fei Lang, Jia Luo, Lan-Ying Sun, Xiao-Ning Wang, Qi-Jun Qian, Xin-Yuan Liu.   

Abstract

Human telomerase reverse transcriptase (hTERT), the catalytic subunit of the telomerase, is transcriptionally upregulated in more than 90% of tumor cells. It may be used as a tool for driving a gene to kill tumors specifically. To test this idea, luciferase reporter gene was used and the results showed that hTERT promoter could restrict the gene expression in the telomerase-positive tumor cells. A tumor-specific expression plasmid phTERT-CD was constructed, in which the E. coli cytosine deaminase (CD) gene was controlled by the hTERT promoter. A colorectal cancer cell line (LoVo) and a normal amnion cell line (WISH) were transfected by this plasmid. It was shown that the expression of the CD gene increased the sensitivity of LoVo cells to the prodrug, 5-fluorocytosine (5FC), over 800-fold, while the sensitivity of WISH cells to 5FC was increased only 6-fold. Mixed cell experiments showed a strong "bystander effect" on CD-negative cells. Furthermore, a significant anti-tumor effect of the phTERT-CD/5FC system was observed in nude mice bearing mammalian carcinoma induced by s.c. inoculation of LoVo cells when the mice were given 250 mg/kg 5FC twice a day for 10 consecutive days. These results indicated that hTERT promoter could target the suicidal effect of CD gene to tumor cells, and therefore, may be a novel and promising targeting approach to the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12168115

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.

Authors:  Yigang Wang; Fang Huang; Haibo Cai; Yumei Wu; Guoqing He; Wen-Song Tan
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-07       Impact factor: 4.553

2.  Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.

Authors:  Alan E Bilsland; Aileen Fletcher-Monaghan; W Nicol Keith
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

Review 3.  Is telomerase a viable target in cancer?

Authors:  C M Buseman; W E Wright; J W Shay
Journal:  Mutat Res       Date:  2011-07-23       Impact factor: 2.433

4.  AAV's anatomy: roadmap for optimizing vectors for translational success.

Authors:  Angela M Mitchell; Sarah C Nicolson; Jayme K Warischalk; R Jude Samulski
Journal:  Curr Gene Ther       Date:  2010-10       Impact factor: 4.391

Review 5.  Targeting telomerase-expressing cancer cells.

Authors:  Michel M Ouellette; Woodring E Wright; Jerry W Shay
Journal:  J Cell Mol Med       Date:  2011-07       Impact factor: 5.310

6.  In vitro and in vivo effect of 5-FC combined gene therapy with TNF-α and CD suicide gene on human laryngeal carcinoma cell line Hep-2.

Authors:  Li-Ping Chai; Zhang-Feng Wang; Wei-Ying Liang; Lei Chen; Dan Chen; An-Xun Wang; Zhao-Qiang Zhang
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.